Glenoaks Pathology Medical Group Inc.

Glenoaks Pathology Medical Group Inc., doing business as Glenoaks Pathology Medical Group In, is a small, minority-owned, woman-owned, and veteran-owned business based in La Crescenta, California that provides autopsy assistant and pathology support services exclusively to federal healthcare agencies as a prime contractor. The company holds Subchapter S Corporation status and carries Hispanic American Owned certification alongside its multi-designator small-business posture. All twelve of Glenoaks' federal awards are prime contracts placed on a full-and-open basis with no set-aside designation, indicating a vendor strategy centered on competing directly rather than leveraging SBA vehicles.

Glenoaks' customer footprint is highly concentrated and stable. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 (VISN 21) accounts for all but one award and virtually all potential value — 11 awards totaling $2.8 million across its entire active portfolio. The single remaining award is a $21 thousand delivery under the Department of the Army Installation Management Command Pacific Region. The vendor's award history spans contracts and an Indefinite Delivery Contract (IDC 36C26124D0058, valued at $700,000 with a ceiling through March 31, 2029) that serves as the parent mechanism for three delivery orders placed between April 2024 and April 2026. Representative work includes a $124,758 delivery order for medical autopsy services at San Francisco VA (April 2026–March 2027), a $121,118 delivery order for autopsy assistant services at San Francisco VA (April 2025–March 2026), and a $117,582 delivery order at La Crescenta-Montrose VA Medical Center (April 2024–March 2025). Earlier, the vendor held a $249,897 purchase order for autopsy assistant services running October 2021 through March 2024.

Activity has been modest and sporadic — one award per year through 2021, then no activity until two awards in 2024, followed by single awards in 2025 and 2026. One award (combined potential value $125 thousand) reaches completion within the next twenty-four months, representing the sole near-term recompete exposure. The vendor generates no subcontract work and operates entirely through prime delivery. Category concentration reflects the narrow capability scope: Medical Laboratories (6 awards) and Offices of All Other Miscellaneous Health Practitioners (3 awards) by NAICS, with Medical-Pathology as the dominant PSC across 8 awards.